The major coronary arteries.
The heart is the vital organ that tirelessly pumps oxygenated blood from the lungs to the organs and peripheral tissues via the circulatory system. In return, deoxygenated blood is returned via the heart and the pulmonary circulation to the lungs to expel waste carbon dioxide (figure 1). The average human heart beats approximately 72 beats per minute totalling around 2.5 billion beats in a 66-year lifespan. The human heart weighs 250-300g in females and 300-350g in males. The heart is located in the mediastinum of the thorax, anterior to the vertebrae and posterior to the sternum.
1.1. Development and anatomy of the coronary arteries
As with any organ, the heart requires its own supply of blood for continued functioning. The supply of blood to the myocardium occurs via the coronary artery circuit (figure 2). Their name is derived from the Latin ‘Corona’, meaning crown as the main vessels encircle the interventricular and atrioventricular grooves.
The arterial tree has two main compartments; firstly, the main arteries (table 1) and ramifications on the surface of the myocardium, known as the extramural coronary system. Secondly, the branches of the surface vessels which penetrate deep into the myocardial tissues are known as the intramural coronary system.
The extramural coronary system is formed from two main arteries. The left coronary artery (LCA) and the right coronary artery (RCA). A third vessel exists in up to 50% of the population and is known as the conus artery. The diameters of the vessels are given in table 1. The intramural coronary system is a complex vascular network containing the main intramural branches which have region specific distribution patterns. The ventricular branches arise at right angles from the subepicardial arteries taking an endocardial route. An important component of the intramural system is the collateral or anastomotic arterial system. These vessels have a characteristic corkscrew appearance. They are present at birth and do not differ in distribution by age or gender. In the normal heart they are 20-350 μm in diameter.
|LEFT CORONARY ARTERY (LCA)||4 (2.5-5.5)|
|Left anterior descending||3.6 (2-5)|
|DG diagonal||2 (0.5-2.5)|
|LCX circumflex||3 (1.5-5)|
|LMG marginal||2.2 (1-3)|
|RIGHT CORONARY ARTERY (RCA)||3.2 (1.5-5.5)|
|RMG marginal||1.7 (1-2.5)|
|PD posterior descending||2.1 (1-3)|
|THIRD CORONARY ARTERY ‘conus artery’||1.1 (0.7-2)|
|Septal branches anterior from LCX||1 (0.5-2.5)|
|Septal branches posterior from PD||0.7 (0.3-0.9)|
|From ascending LAD||0.4 (0.3-0.7)|
The primitive embryonic heart is nourished via lacunar or intertrabeclar spaces, forming a net-like structure separating bundles of muscle fibres. Further evolutionary development results in endothelial budding. Originally this was thought to derive from the coronary sinus and aorta, forming superficial veins and arteries which penetrate into the myocardial tissue joining the lacunar spaces. It was then demonstrated in chick-quail chimaeras that the vessels were derived from the proepicardium structure common to the embryo and undergo a transition from epithelial to mesenchymal tissue. Mouse studies refute this, suggesting that the proepicardium gives rise to myocardial stroma and vascular smooth muscle but not coronary artery endothelial cells. Using clonal and histological analysis in the mouse, Red-Horse and colleagues (Red-Horse et al. 2010) demonstrate that coronary arteries are formed by developmental reprogramming of venous cells, arising from angiogenic sprouts of the sinus venosus which returns blood to the embryonic heart. The understanding of angiogenesis in the myocardium may in future lead to more natural methods to stimulate vascular growth and engineering coronary bypass grafts rather than transplanting veins to revascularize damaged myocardium.
2. Cardiovascular disease
A variety of diseases affect the primary functioning of the heart. Cardiovascular disease (CVD) is the collective name for diseases of the heart and blood vessels of the circulatory system. An atlas of types of cardiovascular diseases in the heart and in the circulation are given in table 2.
International efforts have been implemented to classify and code the different types of ischemic heart diseases. A number of notable indexing databases such as the International Classification of Diseases database, Disease Database eMedicine and MeSH databases have produced indexing codes. These are given in table 3.
|Angina Pectoris||Aortic aneurysm|
|Variant (Prinzmetal’s) Angina|
|Heart block (first-degree and second-degree and complete AV block)||Atherosclerosis|
|Premature atrial complex|
|Atrial flutter||Aortic dissection|
|Paroxysmal supraventricular tachycardia|
|Premature ventricular complex||Essential (primary) hypertension|
|Ventricular tachycardia||Secondary hypertension|
|Ventricaular fibrillation||Malignant hypertension|
|Long QT syndrome|
|Stroke (Cerebrovascular accident)|
|Dilated Cardiomyopathy||Transient ischemic attack|
|Restrictive Cardiomyopathy||Arterial disease|
|Congestive heart failure||Acute arterial occlusion|
|Congenital heart disease||Arteriovenous fistula|
|Atrial septal defect||Vasculitis|
|Ventricular septal defect||Thoracic outlet syndrome|
|Patent ductus arteriosus|
|Pulmonary stenosis||Venous disease|
|Congential aortic stenosis||Venous thrombosis|
|Teratology of Fallot||Deep vein thrombosis|
|Tricuspid atresia||Varicose veins|
|Truncus arteriosus||Spider veins|
|Ebstein’s abnormality of the tricuspid valve|
|Great vessel transposition||Lymphedema|
|Coronary artery disease|
|Ischemic heart disease|
|Acute myocardial infarction|
|Heart valve disease|
|Mitral valve regurgitation|
|Mitral valve prolapse|
|Sudden cardiac death|
|International Classification of Diseases (ICD-9)|
World Health Organisation,
|410||Acute Myocardial infarction (AMI)|
|411||Other acute and subsequent forms of Ischemic Heart Disease|
|412||Old Myocardial Infarction|
|414||Other forms of chronic ischemic heart disease|
|International Classification of Diseases (ICD-10)|
World Health Organisation,
|121||Acute Myocardial Infarction (AMI)|
|122||Subsequent Myocardial Infarction|
|123||Certain current complications following AMI|
|124||Other acute ischemic heart diseases|
|125||Chronic ischemic heart disease|
|Diseases Database (DiseaseDB)|
Medical Object Oriented Software Enterprises Ltd London UK
|8695 - Ischemic or Ischaemic Heart disease, Myocardial Ischaemia, Steoncardia, Angina Pectoris, Coronary Artery Arteriosclerosis, IHD|
New York, USA
|Med/1568 – Angina Pectoris|
|Medical Subject headings (MeSH)|
Unites States National Library of Medicine
Bethesda, Maryland, USA
|D017202 – Myocardial Ischemia|
3. Pathobiology of ischemic heart disease
Hypoxia refers to the physiological or pathological state in which oxygen supply is reduced despite adequate perfusion of the tissue. Anoxia is the absence of oxygen from the tissue, despite being adequately perfused. These are clearly distinguishable from ischemia where oxygen supply is restricted as a direct result of suboptimal tissue perfusion. Ischemic tissue also accumulates toxic metabolites due to the inadequate removal through the capillary and venous blood systems.
The atherosclerotic process responsible for restriction of blood flow in the coronary arteries is a multifactorial process and is initiated by damage to the endothelium. Cholesterol rich low density lipoprotein (LDL) particles enter the intimal layer via the LDL receptor protein (Brown and Goldstein 1979), a mosaic cell surface protein that recognizes apolipoprotein B100 embedded in the LDL particle. It also recognizes apolipoprotein E found in chylomicrons and very low density lipoprotein remnants, or intermediate density lipoprotein. Macrophage cells accumulate oxidized lipid independently of the LDL receptor by endocytosis. This results in formation of juvenile raised fatty streaks within the endothelium. The macrophage release their lipid content and cytokines into the intima. Cytokines stimulate intimal thickening by smooth muscle cell proliferation, which then secrete collagen, causing fibrosis (figure 3). The lesion appears raised and yellow.
As the lesion develops, the medial layer of the vessel wall atrophies and the elastic lamina becomes disrupted. Collagen forms a fibrous cap over the lesion that appears hard and white (known as a fibrolipid plaque). The plaque contains macrophage laden with lipid (foam cells) as well as extracellular or ‘free’ lipid within the lesion. The endothelium is now in a fragile state. Ulceration of the cap occurs at weak points such as the shoulder region, near the endothelial lining. Rupture to the cap can cause turbulent blood flow in the lumen. The exposed lipid core causes aggregation of platelets and development of a thrombosis. This lesion grows due to further platelet aggregation and is responsible for narrowing of the lumen of the artery resulting in localized ischemia. Distal embolization of a piece of such thrombus may travel downstream and can completely occlude smaller arteries.
The symptomatic part of the continuum is known as the acute coronary syndrome (ACS) which is due to the rupture/erosion of the plaque. This produces, depending on the plaque size, vascular anatomy and presence of collateral vessels, a mismatch between the supply and demand for oxygen. A net reduction in supply compared to the demand results in ischemia. Tissue hypoxia proceeds resulting in inadequate blood/oxygen perfusion. If blood flow is not re-established, cardiac cell necrosis will occur. Post AMI survival results in remodelling processes in the myocardium and the development of cardiac failure.
4. Epidemiology of ischemic heart disease
According to the World Health Organisation, chronic diseases of which heart disease is the single largest contributing category; are responsible for 63% of all global deaths (United Nations High-Level Meeting on Noncommunicable Disease Prevention and Control 2012). Non communicable diseases kill 9 million people under the age of 60 every year which has a profound socio-economic impact.
The incidence of Ischemic heart disease (IHD) is higher than for any cancer or other non-CVD condition. Cardiovascular diseases (CVD) are the leading cause of death in the Western World and are dramatically increasing within developing countries. The Age-standardized estimate of mortality by cardiovascular diseases and diabetes per 100,000 people is given in figure 4. 17.1 million people die as a direct result of CVD per year and 82% of these deaths occur in the developing word
It is predicted that by 2030 23 million people will die from a CVD. Data from the USA suggests that CVD was responsible for 34% of deaths in 2006 and over 151,000 Americans who died were <65 years old. The incidence of CVD is declining in the Western World even though rates of lifestyle associated risk factors such as obesity, smoking and type II diabetes mellitus are increasing. The decline is in part due to advances in therapeutic and invasive intervention. In creating better outcomes for those with acute cardiac conditions, patients develop heart failure which requires longer term treatment and monitoring and may in fact be a greater health burden than the acute events themselves.
5. Risk factors
There is no single causative risk factor for the development of IHD. A number of genetic and environmental risk factors have been established as causative in the development of the atherosclerotic lesion. Smoking and obesity cause 36% and 20% of IHD respectively. A large European meta-analysis of 197,473 participants reported an small association between job stress and the development of coronary artery disease (Kivimaki et al. 2012). There has been extensive research linking a sedentary lifestyle and a lack of exercise with a risk of IHD. The major risk factors for the development of IHD are given in table 4.
|Family history of IHD||Obesity (particularly central abdominal obesity)|
|Personal history of early IHD||Tobacco and passive tobacco Smoking|
|Diabetes Mellitus type I||Excessive alcohol consumption|
|Elevated homocysteine||Diabetes Mellitus type II|
|Elevated haemostatic factors||Sedentary lifestyle|
|Baldness & hair greying||Low antioxidant levels|
|Earlobe crease (Frank’s sign)||Infection|
|Air pollution (CO, NO2, SO2)|
|Combined oral contraceptive pill|
6. Signs and symptoms of ischemic heart disease
Ischemia may manifest in many forms. Most commonly, patients present with chest pain on exertion, in cold weather or in emotional situations. This discomfort is known as angina pectoris. Patients may present with acute chest pain at rest which typically radiates down the left arm and up the left side of the neck. Patients may experience nausea, vomiting, sweating and enhanced anxiety. Symptomatically, women present with less ‘textbook’ symptoms and often describe their condition as weakness, indigestion and fatigue (Kosuge et al. 2006). Up to 60% of AMI are referred to as silent without any observation of chest pain or other symptoms (Valensi et al. 2011).
Angina is diagnosed by evidence of deviation of the ST segment on the electrocardiogram, reduced uptake of thallium-201 during myocardial perfusion imaging or regional or global impairment of ventricular function. In patients with stable angina often have chest pain on exertion. Patients benefit from cardiac stress testing, echocardiography. If indicated patients should receive coronary angiography to locate anatomically any stenosis with a view to revascularisation by stenting during percutaneous coronary intervention or coronary artery bypass grafting (CABG) surgery.
7. Diagnosis of ischemic heart disease
In the primary care setting, patients may be suspected of having ischemic heart disease based on risk factor assessment and blood chemistry tests such as lipid profiling, inflammatory markers and homocysteine concentration.
Primarily the diagnosis of IHD occurs in the acute setting when patients present with symptomatic chest pain. Patients often present with a myriad of symptoms which confuse the clinical picture. Patients should receive immediate electrocardiography and pharmacological or surgical intervention in those who demonstrate ST-segment elevation in the context of ST-segment myocardial infarction (STEMI). In suspected non-ST segment elevation myocardial infarction (NSTEMI) patients should undergo serial venepuncture for cardiac biomarkers, namely the cardiac troponins which are indicative of myocyte necrosis. Patients may undergo stress testing, whereby the stress response is induced by exercise or pharmacological agents allowing comparison of the coronary circulation at rest and under stress. Patients are monitored continuously whilst exercising on a treadmill, on a ergometer bicycle or following injection of agents such as adenosine, the adenosine A2A receptor Regadenoson or the beta-agonist dobutamine. The agent of choice is dependent on drug interactions with medication or concomitant disease states.
Cardiac ultrasound or echocardiography by two-dimensional, three-dimensional or Doppler ultrasound create images of the myocardium at work. Transthoracic echocardiogram (TTE) is the commonest form and the ultrasound transducer probe is placed non-invasively on the thorax. Transoesophageal echogram (TOE) is an alternative method where the transducer tip is passed into the oesophagus, allowing imaging directly behind the heart.
8. Treatment of ischemic heart disease
Stable IHD patients can be adequately treated in the primary care setting with emphasis on both lifestyle and risk factor modifications to reduce the risk of a future adverse cardiac event. Modification of lifestyle risk factors such as smoking cessation and weight loss control have a direct impact on risk reduction. Further intervention such as treating hypertension, glycaemic control in diabetics and therapeutic intervention in hyperlipidaemia result in risk reduction. Furthermore, elective revascularisation of occluded coronary arteries may confer a reduction in mortality risk compared to conservative therapy. A meta-analysis of 13,121 patients in whom 6476 were randomised to revascularisation compared to medical treatment in the remainder demonstrated that bypass grafting and Percutaneous coronary intervention are superior to medical therapy alone with respect to 1-10 year mortality (Jeremias et al. 2009).
Patients with symptomatic chest pain suggestive of an AMI and ST segment elevation should receive immediate revascularisation. Fibrinolytic therapy should be administered within 30 minutes and door-to-balloon PCI should occur in no more than 90 minutes from the onset of pain. For non ST segment elevation AMI patients, treatment with aspirin, glycoprotein IIb/IIIa inhibitor such as clopidogrel, low molecular weight heparin, glyceryl trinitrate and opioid therapy for persistent pain.
Ischemic heart disease is the major contributing cause of death in the Western World and the incidence is increasing in developing countries. Successful advances in surgical and therapeutic intervention are able to salvage myocardial tissue and increase prognosis if administered in the early phase following injury.